

B70

(I) antigen is prepd. by reaction of 1 of the peptides (as hapten) and carrier in the presence of hapten-carrier binding agent. Carriers may be natural and synthetic proteins, e.g. animal serum albumin (human serum albumin, bovine serum albumin), animal serum globulin, animal thyroglobulin, animal hemoglobin, lysine-glutamic acid copolymer, polylysine, polyglutamic acid, etc.. Binding agents are, e.g. aliphatic dialdehydes (glyoxal, malondialdehyde), dimaleimides (N,N'-o-phenylene-dimaleimide), maleimide-carboxyl -N-hydroxysuccinimide-esters, carbodiimides, etc..

? S PN=JP 61073665

S8 1 PN=JP 61073665

? T 8/3,AB/1

8/3,AB/1

DIALOG(R) File 351:Derwent WPI

(c) 2003 Thomson Derwent. All rts. reserv.

004632176

WPI Acc No: 1986-135519/*198621*

XRAM Acc No: C86-058161

XRPX Acc No: N86-100158

Protecting wounds by artificial membrane - by applying soln. contg.

anionic polymer and calcium salt soln. contg. cationic polymer to wound

Patent Assignee: KUMABE K (KUMA-I)

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 61073665	A	19860415	JP 84195767	A	19840920	198621 B

Priority Applications (No Type Date): JP 84195767 A 19840920

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
JP 61073665	A		4		

Abstract (Basic): JP 61073665 A

First soln. is prepd. by heating and sterilising at least one anionic macromolecular material aq. soln.. The second soln. is prepd. by adding a calcium salt aq. soln. to at least one cationic macromolecular material aq. solution and by heating and sterilising the calcium salt aq. soln.-contg. cationic macromolecular material aq. soln.. The first soln. and the second soln. are applied to a wound and the surrounding area to form a membrane.

The first soln. is a 0.1-10.0% anionic macromolecular aq. soln.. The second soln. is a soln. prepd. to pH 5 by adding a 5-10.0 % Ca salt aq. soln. to a 0.1-5.0 % cationic macromolecular aq. soln. The anionic macromolecular material is that selected from xanthan gum, alginic acid, and galacturonic acid. The cationic macromolecular material is that selected from chitosan, polylysine and copolymer of dihydroxyethylaminopropyl and glutamic acid. The first soln. and the second soln. are sprayed at the wound and the surrounding area.

USE/ADVANTAGE - The membrane developed has good adhesion to a skin, resulting in protecting the wound and eliminating the need for applying a gauze to the wound.

? S PN=JP 63253028
S9 1 PN=JP 63253028
? T 9/3,AB/1

9/3,AB/1
DIALOG(R)File 351:Derwent WPI
(c) 2003 Thomson Derwent. All rts. reserv.

007707565
WPI Acc No: 1988-341497/*198848*
XRAM Acc No: C88-150996
Biocompatibility promoters - comprises cpd. obtd. by reaction of prod. of protein toxin from enterotoxin, abrin, ricin or viscotoxin and amino-gp. modifying agent

Patent Assignee: KAO CORP (KAOS)
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 63253028	A	19881020	JP 8786632	A	19870408	198848 B

Priority Applications (No Type Date): JP 8786632 A 19870408
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
JP 63253028	A		7		

Abstract (Basic): JP 63253028 A
Promoters contain as active component a cpd. obtd. with a reaction of (a) 1 mol of protein toxin selected from cholera enterotoxin, abrin, ricin or viscotoxin and (b) 1-10 mol of amino radical chemically modifying agent.
Pref. abrin is obtd. from seed of Abrus precatorium L. Viscotoxin is obtd. from the plant (Viscum albam L). The chemically modifying agent is polyethyleneoxide, 3,5-bis(o-methoxy polyethyleneglycol) triazine; a copolymer of lysine and polyaspartic acid, polyalanine, polylysine or glutamic acid; 3,5-bis(pullulan) triazine, dextran; propionic acid, capronic acid, caproic acid, lauric acid, etc.
USE/ADVANTAGE - Promoters are useful for immuno rejection reaction inhibitors.

? S PN=FR 2092875
S10 1 PN=FR 2092875
? T 10/3,AB/1

10/3,AB/1
DIALOG(R)File 351:Derwent WPI
(c) 2003 Thomson Derwent. All rts. reserv.

000866188
WPI Acc No: 1972-26165T/*197217*
Interferon stimulants - dialkylaminoalkyl dextran-nucleic acid comple
Patent Assignee: MAES RFE (MAE -I)
Number of Countries: 002 Number of Patents: 002
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
FR 2092875	A					197217 B
US 3679654	A					197232

Priority Applications (No Type Date): FR 7023769 A 19700626